ALT Altimmune Inc

Altimmune to Announce Third Quarter 2020 Financial Results on November 10

Altimmune to Announce Third Quarter 2020 Financial Results on November 10

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.

Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.

Conference Call Details

Date:Tuesday, November 10th
Time:8:30 am Eastern Time
Domestic:877-300-8521
International:412-317-6026
Conference ID:10149733
Webcast:

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit .

Investor Contacts:  
Will Brown Ashley R. Robinson
Chief Financial Officer LifeSci Advisors, LLC
Phone: 240-654-1450 617-430-7577
 
   
Media Contacts:  
Warren Rizzi  
Sard Verbinnen & Co.  
Phone: 212-687-8080  
  
EN
03/11/2020

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from ...

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-bas...

15m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Third Quarter 2025 Financial Results and Business ...

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened with Appointments of Chief Medical Officer, Chief Commercial Officer, and Chief Legal Officer Cash, cash equivalents and short-term investments of $211 million as of September 30, 2025 Webcast to be held today, November 6, 2025, at 8:30 a.m. ET GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT)...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare ConferenceWednesday, November 12, 2025Fireside Chat at 10:00 a.m. ET Jefferies Global Healthcare ConferenceThursday, November 20, 2025Fireside Chat ...

November 5, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 ...

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the completion of patient enroll...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Third Quarter 2025 Financial Results and Provide B...

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live ...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch